These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

121 related items for PubMed ID: 12105221

  • 1. Overexpression of the atypical protein kinase C zeta reduces topoisomerase II catalytic activity, cleavable complexes formation, and drug-induced cytotoxicity in monocytic U937 leukemia cells.
    Plo I, Hernandez H, Kohlhagen G, Lautier D, Pommier Y, Laurent G.
    J Biol Chem; 2002 Aug 30; 277(35):31407-15. PubMed ID: 12105221
    [Abstract] [Full Text] [Related]

  • 2. A role for PKCzeta in potentiation of the topoisomerase II activity and etoposide cytotoxicity by wortmannin.
    Reis C, Giocanti N, Hennequin C, Mégnin-Chanet F, Fernet M, Filomenko R, Bettaieb A, Solary E, Favaudon V.
    Mol Cancer Ther; 2005 Oct 30; 4(10):1457-64. PubMed ID: 16227394
    [Abstract] [Full Text] [Related]

  • 3. Protein kinase C-zeta overexpression induces erythroid phenotype in the monocytic leukaemia cell line U937.
    Mansat-De Mas V, de Thonel A, Gaulin V, Demur C, Laurent G, Quillet-Mary A.
    Br J Haematol; 2002 Aug 30; 118(2):646-53. PubMed ID: 12139760
    [Abstract] [Full Text] [Related]

  • 4. Hypophosphorylation of topoisomerase II in etoposide (VP-16)-resistant human leukemia K562 cells associated with reduced levels of beta II protein kinase C.
    Ritke MK, Murray NR, Allan WP, Fields AP, Yalowich JC.
    Mol Pharmacol; 1995 Nov 30; 48(5):798-805. PubMed ID: 7476909
    [Abstract] [Full Text] [Related]

  • 5. Human small cell lung cancer NYH cells selected for resistance to the bisdioxopiperazine topoisomerase II catalytic inhibitor ICRF-187 demonstrate a functional R162Q mutation in the Walker A consensus ATP binding domain of the alpha isoform.
    Wessel I, Jensen LH, Jensen PB, Falck J, Rose A, Roerth M, Nitiss JL, Sehested M.
    Cancer Res; 1999 Jul 15; 59(14):3442-50. PubMed ID: 10416608
    [Abstract] [Full Text] [Related]

  • 6. Formation of topoisomerase II alpha complexes with nascent DNA is related to VM-26-induced cytotoxicity.
    Qiu J, Catapano CV, Fernandes DJ.
    Biochemistry; 1996 Dec 17; 35(50):16354-60. PubMed ID: 8973211
    [Abstract] [Full Text] [Related]

  • 7. Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines.
    Sehested M, Wessel I, Jensen LH, Holm B, Oliveri RS, Kenwrick S, Creighton AM, Nitiss JL, Jensen PB.
    Cancer Res; 1998 Apr 01; 58(7):1460-8. PubMed ID: 9537249
    [Abstract] [Full Text] [Related]

  • 8. Reduction in drug-induced DNA double-strand breaks associated with beta1 integrin-mediated adhesion correlates with drug resistance in U937 cells.
    Hazlehurst LA, Valkov N, Wisner L, Storey JA, Boulware D, Sullivan DM, Dalton WS.
    Blood; 2001 Sep 15; 98(6):1897-903. PubMed ID: 11535527
    [Abstract] [Full Text] [Related]

  • 9. The role of cell cycle regulation and apoptosis triggering in determining the sensitivity of leukemic cells to topoisomerase I and II inhibitors.
    Dubrez L, Goldwasser F, Genne P, Pommier Y, Solary E.
    Leukemia; 1995 Jun 15; 9(6):1013-24. PubMed ID: 7596166
    [Abstract] [Full Text] [Related]

  • 10. Altered stability of etoposide-induced topoisomerase II-DNA complexes in resistant human leukaemia K562 cells.
    Ritke MK, Roberts D, Allan WP, Raymond J, Bergoltz VV, Yalowich JC.
    Br J Cancer; 1994 Apr 15; 69(4):687-97. PubMed ID: 8142256
    [Abstract] [Full Text] [Related]

  • 11. Reduced phosphorylation of topoisomerase II in etoposide-resistant human leukemia K562 cells.
    Ritke MK, Allan WP, Fattman C, Gunduz NN, Yalowich JC.
    Mol Pharmacol; 1994 Jul 15; 46(1):58-66. PubMed ID: 8058057
    [Abstract] [Full Text] [Related]

  • 12. Alterations in the topoisomerase II alpha gene, messenger RNA, and subcellular protein distribution as well as reduced expression of the DNA topoisomerase II beta enzyme in a mitoxantrone-resistant HL-60 human leukemia cell line.
    Harker WG, Slade DL, Parr RL, Feldhoff PW, Sullivan DM, Holguin MH.
    Cancer Res; 1995 Apr 15; 55(8):1707-16. PubMed ID: 7712479
    [Abstract] [Full Text] [Related]

  • 13. DNA topoisomerase II-dependent cytotoxicity of alkylaminoanthraquinones and their N-oxides.
    Smith PJ, Blunt NJ, Desnoyers R, Giles Y, Patterson LH.
    Cancer Chemother Pharmacol; 1997 Apr 15; 39(5):455-61. PubMed ID: 9054961
    [Abstract] [Full Text] [Related]

  • 14. Characterization of an unusual mutant of human melanoma cells resistant to anticancer drugs that inhibit topoisomerase II.
    Campain JA, Padmanabhan R, Hwang J, Gottesman MM, Pastan I.
    J Cell Physiol; 1993 May 15; 155(2):414-25. PubMed ID: 8097746
    [Abstract] [Full Text] [Related]

  • 15. Resistance to antitumor agent-induced apoptosis in a mutant of human myeloid leukemia U937 cells.
    Kataoka S, Naito M, Tomida A, Tsuruo T.
    Exp Cell Res; 1994 Nov 15; 215(1):199-205. PubMed ID: 7957669
    [Abstract] [Full Text] [Related]

  • 16. Mechanism of cytotoxicity of N-[2-(dimethylamino)ethyl] acridine-4-carboxamide and of its 7-chloro derivative: the roles of topoisomerases I and II.
    Bridewell DJ, Finlay GJ, Baguley BC.
    Cancer Chemother Pharmacol; 1999 Nov 15; 43(4):302-8. PubMed ID: 10071981
    [Abstract] [Full Text] [Related]

  • 17. Quantification of topoisomerase-DNA complexes in leukemia cells from patients undergoing therapy with a topoisomerase-directed agent.
    Ellis AL, Nowak B, Plunkett W, Zwelling LA.
    Cancer Chemother Pharmacol; 1994 Nov 15; 34(3):249-56. PubMed ID: 8004759
    [Abstract] [Full Text] [Related]

  • 18. Attenuation of drug-stimulated topoisomerase II-DNA cleavable complex formation in wild-type HL-60 cells treated with an intracellular calcium buffer is correlated with decreased cytotoxicity and site-specific hypophosphorylation of topoisomerase IIalpha.
    Aoyama M, Grabowski DR, Dubyak GR, Constantinou AI, Rybicki LA, Bukowski RM, Ganapathi MK, Hickson ID, Ganapathi R.
    Biochem J; 1998 Dec 15; 336 ( Pt 3)(Pt 3):727-33. PubMed ID: 9841887
    [Abstract] [Full Text] [Related]

  • 19. Antagonistic effect of aclarubicin on the cytotoxicity of etoposide and 4'-(9-acridinylamino)methanesulfon-m-anisidide in human small cell lung cancer cell lines and on topoisomerase II-mediated DNA cleavage.
    Jensen PB, Sørensen BS, Demant EJ, Sehested M, Jensen PS, Vindeløv L, Hansen HH.
    Cancer Res; 1990 Jun 01; 50(11):3311-6. PubMed ID: 2159380
    [Abstract] [Full Text] [Related]

  • 20. Increased phosphorylation of DNA topoisomerase II in etoposide resistant mutants of human glioma cell line.
    Matsumoto Y, Kunishio K, Nagao S.
    J Neurooncol; 1999 Jun 01; 45(1):37-46. PubMed ID: 10728908
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.